S&P 500   4,567.56 (+0.28%)
DOW   35,539.90 (+0.35%)
QQQ   391.28 (+0.28%)
AAPL   189.88 (-0.27%)
MSFT   378.28 (-1.15%)
META   333.82 (-1.53%)
GOOGL   135.65 (-1.13%)
AMZN   146.44 (-0.40%)
TSLA   247.95 (+0.50%)
NVDA   482.19 (+0.83%)
NIO   7.23 (+0.28%)
BABA   74.78 (-2.55%)
AMD   124.60 (+2.12%)
T   16.24 (+0.37%)
F   10.63 (+2.51%)
MU   77.28 (+1.52%)
CGC   0.55 (+1.81%)
GE   119.45 (+0.50%)
DIS   92.88 (+0.41%)
AMC   7.06 (+5.37%)
PFE   30.03 (+1.15%)
PYPL   58.64 (+0.29%)
XOM   103.11 (-0.76%)
S&P 500   4,567.56 (+0.28%)
DOW   35,539.90 (+0.35%)
QQQ   391.28 (+0.28%)
AAPL   189.88 (-0.27%)
MSFT   378.28 (-1.15%)
META   333.82 (-1.53%)
GOOGL   135.65 (-1.13%)
AMZN   146.44 (-0.40%)
TSLA   247.95 (+0.50%)
NVDA   482.19 (+0.83%)
NIO   7.23 (+0.28%)
BABA   74.78 (-2.55%)
AMD   124.60 (+2.12%)
T   16.24 (+0.37%)
F   10.63 (+2.51%)
MU   77.28 (+1.52%)
CGC   0.55 (+1.81%)
GE   119.45 (+0.50%)
DIS   92.88 (+0.41%)
AMC   7.06 (+5.37%)
PFE   30.03 (+1.15%)
PYPL   58.64 (+0.29%)
XOM   103.11 (-0.76%)
S&P 500   4,567.56 (+0.28%)
DOW   35,539.90 (+0.35%)
QQQ   391.28 (+0.28%)
AAPL   189.88 (-0.27%)
MSFT   378.28 (-1.15%)
META   333.82 (-1.53%)
GOOGL   135.65 (-1.13%)
AMZN   146.44 (-0.40%)
TSLA   247.95 (+0.50%)
NVDA   482.19 (+0.83%)
NIO   7.23 (+0.28%)
BABA   74.78 (-2.55%)
AMD   124.60 (+2.12%)
T   16.24 (+0.37%)
F   10.63 (+2.51%)
MU   77.28 (+1.52%)
CGC   0.55 (+1.81%)
GE   119.45 (+0.50%)
DIS   92.88 (+0.41%)
AMC   7.06 (+5.37%)
PFE   30.03 (+1.15%)
PYPL   58.64 (+0.29%)
XOM   103.11 (-0.76%)
S&P 500   4,567.56 (+0.28%)
DOW   35,539.90 (+0.35%)
QQQ   391.28 (+0.28%)
AAPL   189.88 (-0.27%)
MSFT   378.28 (-1.15%)
META   333.82 (-1.53%)
GOOGL   135.65 (-1.13%)
AMZN   146.44 (-0.40%)
TSLA   247.95 (+0.50%)
NVDA   482.19 (+0.83%)
NIO   7.23 (+0.28%)
BABA   74.78 (-2.55%)
AMD   124.60 (+2.12%)
T   16.24 (+0.37%)
F   10.63 (+2.51%)
MU   77.28 (+1.52%)
CGC   0.55 (+1.81%)
GE   119.45 (+0.50%)
DIS   92.88 (+0.41%)
AMC   7.06 (+5.37%)
PFE   30.03 (+1.15%)
PYPL   58.64 (+0.29%)
XOM   103.11 (-0.76%)

Oxford Biomedica Share Price, News & Analysis (LON:OXB)

GBX 172.60
+0.60 (+0.35%)
(As of 04:45 PM ET)
Compare
Today's Range
171
175.21
50-Day Range
171.80
307.50
52-Week Range
171
575
Volume
233,564 shs
Average Volume
154,376 shs
Market Capitalization
£167.04 million
P/E Ratio
N/A
Dividend Yield
4.57%
Price Target
GBX 605

Oxford Biomedica MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
250.5% Upside
GBX 605 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
£12.12 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars


OXB stock logo

About Oxford Biomedica Stock (LON:OXB)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

OXB Stock Price History

OXB Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Oxford Biomedica Posts FY Loss
CGT CDMO Market Share and Forecast till 2030
See More Headlines
Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
891
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 605
High Stock Price Target
GBX 1,010
Low Stock Price Target
GBX 310
Potential Upside/Downside
+250.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
£-61,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£119.02 million
Cash Flow
GBX 57.34 per share
Book Value
GBX 178 per share

Miscellaneous

Free Float
N/A
Market Cap
£166.85 million
Optionable
Not Optionable
Beta
1.02
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Stuart Paynter (Age 50)
    CFO, Company Secretary & Director
    Comp: $832k
  • Dr. Frank Mathias (Age 61)
    CEO & Director
  • Mr. Thierry Cournez
    COO & Site Head of UK Operations
  • Dr. James Miskin Ph.D.
    Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D.
    Chief Scientific Officer
  • Mr. Matthew Treagus
    Chief Information Officer & Chief of Staff
  • Sophia Bolhassan
    Head of Investor Relations
  • Ms. Natalie Louise Walter
    General Counsel
  • Ms. Lisa James
    Chief People Officer
  • Ms. Kati Hudson
    Head of Intellectual Property and Contracts














OXB Stock Analysis - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares.
View OXB analyst ratings
or view top-rated stocks.

What is Oxford Biomedica's stock price target for 2024?

3 brokerages have issued 12-month price targets for Oxford Biomedica's shares. Their OXB share price targets range from GBX 310 to GBX 1,010. On average, they anticipate the company's share price to reach GBX 605 in the next year. This suggests a possible upside of 250.5% from the stock's current price.
View analysts price targets for OXB
or view top-rated stocks among Wall Street analysts.

How have OXB shares performed in 2023?

Oxford Biomedica's stock was trading at GBX 442.50 at the start of the year. Since then, OXB stock has decreased by 61.0% and is now trading at GBX 172.60.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:OXB) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -